• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Saturday, March 6, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Heparin targets coronavirus spike protein, research shows

Bioengineer by Bioengineer
January 28, 2021
in Biology
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Common anticoagulant drug could be repurposed for Covid-19 treatment

IMAGE

Credit: Mycroft-West et al.

An international team of researchers led by the Universities of Liverpool and Keele, working with Public Health England, has found that the common anticoagulant drug heparin inhibits the SARS-Cov2 virus spike protein, by reducing the virus’ ability to attach to human cells and infect them.

The research, published in the journals British Journal of Pharmacology, and Thrombosis and Haemostasis, found that heparin interacts with the spike protein on the surface of coronavirus (SARS-CoV2), destabilising its structure and preventing it from docking with the ACE2 receptor on human cells.

Molecular modelling by collaborators at Queensland University in Australia showed how heparin can stick to the surface of the spike protein to achieve these effects, and studies with live SARS-CoV2 virus carried out at Public Health England’s Porton Down laboratory showed that unfractionated heparin (but not low molecular weight heparins) could inhibit cell infectivity at doses similar to those currently used in clinical settings as an anticoagulant.

Crucially, the data strongly supported the clinical testing of inhaled (“nebulised”) unfractionated heparin, since the doses known to be delivered to the lungs would have very strong anti-viral effects.

Professor Jeremy Turnbull from the Department of Biochemistry and Systems Biology at the University of Liverpool said: “This is exciting news since heparin could be rapidly repurposed to help alleviate Covid-19 infections, or possibly as a prophylactic treatment for high-risk groups such as medical staff or care workers. The results have also led us to investigate other novel compounds which mimic heparin that could potentially be effective against SARS-CoV2.”

Dr Mark Skidmore from the School of Life Sciences at Keele University co-led the research. He said: “We also know that heparins inhibit a range of other viruses, so studying these drugs could provide new therapeutic strategies, and possibly a first-line of defence against emerging viral threats in the future, for example while vaccines are developed.”

Professor Miles Carroll, of the National Infection Service, Public Health England added: “New treatments which target the SARS-CoV2 virus are urgently needed. Heparin, with its well-known clinical safety profile, is certainly an interesting candidate for repurposing against Covid-19.”

“The Covid-19 pandemic has had a significant impact on the delivery of NHS services and local communities. These results strengthen the need for further investigation of heparin as a treatment in Covid-19 patients,” said Dr Quentin Nunes, Consultant at the East Lancashire Hospitals NHS Trust, who is leading efforts to begin clinical trial of nebulised heparin in ITU patients in the UK.

The early release of preprint data from this study in March 2020, now published in peer-reviewed journals, has stimulated international efforts to explore the use of heparins for Covid-19 treatment. Further work is now ongoing to explore the potential of heparin and heparin-mimicking compounds as potential broad-spectrum antiviral drugs for Covid-19 and other emerging viral threats.

###

Media Contact
Nicola Frost
[email protected]

Related Journal Article

http://dx.doi.org/10.1055/s-0040-1721319

Tags: BiochemistryBiologyInfectious/Emerging DiseasesPharmaceutical ScienceVirology
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

What can stream quality tell us about quality of life?

March 5, 2021
IMAGE

Species traded legally through Hong Kong with inadequate traceability

March 5, 2021

Switzerland’s energy transition

March 5, 2021

‘Falling insect’ season length impacts river ecosystems

March 5, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    668 shares
    Share 267 Tweet 167
  • People living with HIV face premature heart disease and barriers to care

    84 shares
    Share 34 Tweet 21
  • Global analysis suggests COVID-19 is seasonal

    39 shares
    Share 16 Tweet 10
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    36 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Climate ChangecancerMaterialsCell BiologyChemistry/Physics/Materials SciencesBiologyTechnology/Engineering/Computer ScienceInfectious/Emerging DiseasesPublic HealthEcology/EnvironmentMedicine/HealthGenetics

Recent Posts

  • “Magic sand” might help us understand the physics of granular matter
  • Study reveals how egg cells get so big
  • Survey identifies factors in reducing clinical research coordinator turnover
  • New ‘split-drive’ system puts scientists in the (gene) driver seat
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In